In CBO’s current assessment, the new law will affect price negotiations for several orphan drugs not originally included in the estimates of budgetary effects of section 71203 of the 2025 reconciliation act. After incorporating those drugs into its analysis, CBO now estimates that the 10-year cost of the section will be $8.8 billion.
